Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy (Kiryluk, Nature Genetics 2023)
🤔 Sibeprenlimab in IgA Nephropathy
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (Mathur, NEJM 2024)
🤔 Sparsentan in IgA Nephropathy
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (Rovin, Lancet 2023)
🤔 Severe hypocalcemia with Denosumab in Dialysis
Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients (JAMA 2024)
🤔 Cystatin C better predicts outcomes in Sweden
Association of Low Glomerular Filtration Rate With Adverse Outcomes at Older Age in a Large Population With Routinely Measured Cystatin C (Annals IM 2024)
🤔 Flozination reduces kidney stones
Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes (JAMA 2024)
🤔 Maternal kidney mass associates with gestational and fetal outcomes
Any reduction in maternal kidney mass makes a difference during pregnancy in gestational and fetal outcome. (Kidney International 2024)
🤔 Adjusting Tolvaptan based on Urine osmolality in ADPKD
Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD (KI Reports Jan 2024)
KDIGO 2024 Lupus Nephritis Guidelines - Visual Abstract
Hungry Like The Wolf for New Lupus Nephritis Guidance
Is Eculizumab a good Complement in STEC-HUS?
ECULIZUMAB in STEC - HUS - a Visual Abstract
Is eculizumab effective in pediatric patients with Shiga toxin-related E. Coli hemolytic uremic syndrome?
Check out the visual abstract by Melvin Chan for the answer.
Top Stories in Nephrology 2023
2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!
Aldosterone Synthase Inhibitors in Proteinuric CKD: the Visual Abstract
Yet another new medication class for use in the RAAS cascade. BI 690517, an aldosterone synthase inhibitor, has been shown to significantly reduce proteinuria with or without empagliflozin. VA by Brian Rifkin.
Two’s Company but Three maybe the Winner? Aldosterone Synthase Inhibition added to RASi + Flozin
Which were the Top Nephrology Stories of 2023?
ACE-ing the SPACE Trial: traversing the seas of RAS inhibition in non-cardiac surgery
SPACE trial - The Visual abstract
Does the cessation of RAS inhibitors prior to surgery contribute to reduced myocardial injury? Check out the SPACE TRIAL visual abstract by NSMC intern Ali Rizvi
ZENITH: the visual abstract
A very colourful visual abstract from Sabarinath!
